SENSEX    35144.49       331.50    |    NIFTY    10582.5       100.30 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Suven Life Sciences gains after securing product patents in Israel, Japan
06-Nov-18   11:14 Hrs IST

The announcement was made during trading hours today, 6 November 2018.

Meanwhile, the S&P BSE Sensex was up 113.38 points, or 0.32% to 35,064.30.

On the BSE, 18,000 shares were traded in the counter so far compared with average daily volumes of 86,000 shares in the past two weeks. The stock had hit a high of Rs 245.50 and a low of Rs 239.55 so far during the day. The stock hit a 52-week high of Rs 337.70 on 11 September 2018. The stock hit a 52-week low of Rs 163.30 on 23 March 2018.

Suven Life Sciences (Suven) announced securing the grant of one product patent from Israel and one product patent from Japan corresponding to the new chemical entities for the treatment of disorders associated with Neurodegenerative diseases. Patents are valid through 2036 and 2034 respectively.

The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.

Net profit of Suven Life Sciences rose 31.35% to Rs 38.84 crore on 34.51% rise in net sales to Rs 184.88 crore in Q1 June 2018 over Q1 June 2017.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.87 81.89 1.12
United Kingdom (GBP) 1.15 1.00 93.78 1.29
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.89 0.78 72.89 1.00
Commodities << ALL Commodities
GOLDAHMD31200-573
SILVERAHMD36947-1258
CRUDEOILMUMBAI4378-51
COPPERMUMBAI430.45-9.95
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INB010982739   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2008 certified)